Hi everyone,
My name’s Kira and I work in the Policy, Evidence and Influencing team at Breast Cancer Now.
We’re looking to hear from anyone with experience of the treatment elacestrant (also known as korserdu) which is used for treating ER-positive, HER2-negative secondary breast cancer with an ESR1 mutation. You may have received this treatment through a clinical trial.
The treatment is being assessed by the Scottish Medicines Consortium (SMC) to see if it should be made available through NHSScotland and we would love to hear your views to help shape our submission.
It’s crucial that the SMC hears the voices of patients as part of their assessment. If you’d like to share your views on this treatment, please email policy@breastcancernow.org by 5pm on Wednesday 16 July. Your views will be shared completely anonymously.
Thank you!